Gut microbiome analysis could guide probiotic and prebiotic interventions that optimize both natural GLP-1 production and autoimmune management
Contrave may not be the right treatment option if you have certain medical conditions or other factors affecting your health
The choice between the two often depends on availability, cost, and how your body responds to the medication
SELECT Trial: The Evidence for CV Coverage The SELECT trial (published in NEJM, November 2023) demonstrated that Wegovy reduces cardiovascular events: [27] 20% reduction in major adverse cardiovascular events (MACE) Includes heart attacks, strokes, and cardiovascular death 17,604 participants followed for ~3.3 years All participants had established cardiovascular disease plus obesity/overweight Typical Plan Coverage Criteria for CV Indication Medicare plans that cover Wegovy for cardiovascular risk reduction typically require: Clinical Criteria Established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) BMI (body mass index) 27 kg/m No Type 2 diabetes (or T2D not adequately controlled) Concurrent lifestyle modifications (diet and exercise) Required Documentation Cardiology records documenting established CVD Current BMI (height and weight within last 30 days) Letter of Medical Necessity from cardiologist or primary care provider Documentation of lifestyle modification attempts ICD-10 Codes for CV vs
Metabolic Profile Beyond Fat Loss Tesamorelins visceral fat reduction translates into measurable metabolic improvements
United Progressive Alumni
